Filter
256
Filtered Results: 256
Text search:
African
Trypanosomiasis
Featured
Recommendations
30
New Publications
54
Language
Document type
No document type
100
Studies & Reports
71
Guidelines
33
Strategic & Response Plan
24
Manuals
13
Situation Updates
4
Resource Platforms
4
Training Material
3
Infographics
2
Videos
1
Fact sheets
1
Countries / Regions
Africa
25
Global
24
Uganda
15
Congo, Democratic Republic of
10
West and Central Africa
9
East and Southern Africa
8
Liberia
7
Sierra Leone
5
Malawi
5
Middle East and North Africa
5
South Africa
5
Kenya
4
Ghana
4
Latin America and the Carribbean
4
Tanzania
4
Zambia
4
South Sudan
4
Benin
3
Burkina Faso
3
Guinea
3
Southern Africa
3
Central African Republic
3
Chad
3
India
3
Rwanda
2
Cameroon
2
Nigeria
2
Western and Central Europe
2
Côte d’Ivoire / Ivory Coast
2
Bolivia
2
Angola
2
Colombia
1
El Salvador
1
Syria
1
Iran
1
Senegal
1
Niger
1
Afghanistan
1
Zimbabwe
1
Qatar
1
Asia
1
Jordan
1
Saudi Arabia
1
South–East Asia Region
1
Western Pacific Region
1
North America
1
Lebanon
1
Djibouti
1
Egypt
1
Sudan
1
Yemen
1
Palestine
1
Mali
1
Libya
1
Botswana
1
Iraq
1
Somalia
1
Pakistan
1
Authors & Publishers
Publication Years
Category
Countries
78
Clinical Guidelines
36
Public Health
30
Capacity Building
9
Key Resources
7
Women & Child Health
5
Pharmacy & Technologies
5
Toolboxes
NTDs
82
Rapid Response
18
Planetary Health
13
Pharmacy
8
Ebola
6
Caregiver
6
HIV
5
AMR
5
Mental Health
3
TB
3
COVID-19
3
NCDs
3
Conflict
2
Refugee
1
Natural Hazards
1
Disability
1
Cholera
1
Social Ethics
1
Global Health Education
1
Human African trypanosomiasis (HAT), or sleeping sickness, is an endemic disease in 36 sub-Saharan African countries, typically occurring in underdeveloped areas, where
health systems face significant difficulties of diverse natures.
FIND and Standard Diagnostics (SD) have developed a lateral flow rapid diagnostic test (RDT) to screen for
T.b. gambiense HAT that is cheap and easy to use. The tests are packed individually and are stable at 40°C for
up to 25 months; they are performed on fresh blood obtained from a finger prick...
The twentieth century ended with human African trypanosomiasis (HAT) epidemics raging across many parts of Africa. Resistance to existing drugs was emerging, and many programs aiming to contain the disease had ground to a halt, given previous success against HAT and the competing priorities associat...
The development of this target product profile (TPP) was led by the WHO Department of Control of Neglected Tropical Diseases (NTD) following standard WHO guidance for TPP development. In order to identify and prioritize diagnostic needs, a WHO NTD Diagnostics Technical Advisory Group (DTAG) was form...
The development of this target product profile (TPP) was led by the WHO Department of Control of Ne-
glected Tropical Diseases (NTD) following standard WHO guidance for TPP development. In order to
identify and prioritize diagnostic needs, a WHO NTD Diagnostics Technical Advisory Group (DTAG)
was...
The objectives of the meeting were:
1. To update the current status of the disease transmission, country capacities and plans for tackling the disease.
2. To understand the epidemiology including disease distribution and risk, the models
for estimating under-detection, the geographical variati...
The epidemiology of the disease is mediated by the interaction of the parasite (trypanosome) with the vectors (tsetse flies), as well as with the human and animal hosts within a particular environment. Related to these interactions, the disease is confined in spatially limited areas called “foci...
The main purpose of the meeting was to review tsetse control tools, activities and their contribution to the elimination of gHAT and the monitoring thereof. Seven endemic countries provided reports on recent and ongoing vector control interventions at the national level (Angola, Cameroon, Côte d’...
Treatment of second-stage gambiense human African trypanosomiasis relied on toxicarsenic-based derivatives for over 50 years. The availability and subsequent use of eflornithine,initially in monotherapy and more recently in combination with nifurtimox (NECT), has drasticallyimproved the pro...
In support of the London Declaration goals, PATH aims to catalyze engagement of the diagnostics industry and product development efforts. As part of this work, PATH conducted a diagnostic landscape analysis to identify gaps and evaluated current and nascent HAT diagnostics that may provide solutions...
This report provides a review and analysis of the research landscape for three diseases – Chagas disease, human African trypanosomiasis and leishmaniasis – that disproportionately afflict poor and remote populations with limited access to health services. It represents the work of the disease re...
A clear understanding of the knowledge, attitudes and practices (KAP) of a particular community is necessary in order to improve control of human African trypanosomiasis (HAT).New screening and diagnostic tools and strategies were introduced into South Sudan, as part of integrated delivery of primar...
This analysis focused on the chronic form of HAT caused by T. b. gambiense, as it contributes to the majority of disease burden. Information from the literature review,
product development landscape, and stakeholder interviews was compiled to:
- Identify use cases and understand current diagnosti...
The previous report of the WHO Expert Committee on this disease
followed a meeting in 1995. Intensive, coordinated efforts against HAT during
the intervening 18 years have resulted in a decrease in incidence to a point at
which elimination is considered feasible. This report provides informati...
WHO convened the fifth stakeholders meeting on the elimination of HAT due to infection with Trypanosoma brucei gambiense (g-HAT) and Trypanosoma brucei rhodesiense (r-HAT) in Geneva, Switzerland, on 7–9 June 2023. The meeting was held again in person after the coronavirus disease (COVID-19) pandem...
This toolkit for integrated vector management (IVM) is designed to help national and regional programme managers coordinate across sectors to design and run large IVM programmes.
The toolkit provides the technical detail required to plan, implement, monitor and evaluate an IVM approach. IVM can...
The toolkit provides the technical detail required to plan, implement, monitor and evaluate an IVM approach. IVM can...
DNDi’s long-term goal for sleeping sickness, also known as human African trypanosomiasis (HAT), is to develop and register two new drugs that are effective against both Stage 1 and Stage 2 of the disease and both subspecies of the parasite, T.b. gambiense and T.b. rhodesiense. T.b. rhodesiense is ...
Full Perscribing information on Fexinidazole Tablet for oral use
INDICATIONS AND USAGE
Fexinidazole Tablets are indicated for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in pati...
Chapter 6 contents
Malaria
Human African trypanosomiasis (sleeping sickness)
American trypanosomiasis (Chagas disease)
Leishmaniases
Intestinal protozoan infections (parasitic diarrhoea)
Flukes
Schistosomiases
Cestodes
Nematode infections
Filariasis
...
This toolkit for integrated vector management (IVM) is designed to help national and regional programme managers coordinate across sectors to design and run large IVM programmes.
The toolkit provides the technical detail required to plan, implement, monitor and evaluate an IVM approach. IVM can be ...
